» Articles » PMID: 2360819

Theophylline Dosage Adjustment During Enoxacin Coadministration

Overview
Specialty Pharmacology
Date 1990 May 1
PMID 2360819
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Based on the results of a previous study which demonstrated a 50% reduction in theophylline clearance during coadministration of 400 mg of enoxacin twice a day (b.i.d.), a sequential-design study was completed with seven nonsmoking, healthy adult female human volunteers. The subjects were given 200 mg of theophylline (Theo-Dur) orally every 12 h for 4 days. On day 5, the subjects began receiving 400 mg of enoxacin with each theophylline dose, and the dosage of theophylline was reduced to 100 mg b.i.d. This regimen was continued through day 8, after which enoxacin was discontinued. The theophylline dosage was increased to 200 mg b.i.d. on day 9, and theophylline monotherapy continued through day 12. The mean apparent theophylline clearance decreased by approximately 50% during enoxacin coadministration. No significant differences in mean theophylline maximum concentration in serum, time to maximum concentration in serum, lowest concentration observed, or area under the concentration-time curve during the steady-state dosing were observed before, during, or after enoxacin coadministration when the theophylline dosage was reduced to 100 mg b.i.d. Reduction of the theophylline dose by 50% at the onset of enoxacin dosing maintained constant theophylline concentrations in plasma. A return to the original theophylline dose immediately upon cessation of enoxacin therapy resulted in a transient 35% increase in theophylline concentrations in plasma which lasted 24 to 48 h before returning to preenoxacin values. Although a 50% reduction in the theophylline dose maintained constant mean theophylline concentrations when enoxacin was administered concomitantly, it appears that larger dose reductions (up to 75%) could be required in patients with high theophylline clearances. In addition, larger transient increases in the theophylline concentration in plasma may be observed in these patients upon cessation of enoxacin therapy if the theophylline dose is immediately returned to normal. Thus, it is recommended that theophylline concentrations in plasma be monitored when concurrent enoxacin therapy is required.

Citing Articles

Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Pea F, Furlanut M Clin Pharmacokinet. 2001; 40(11):833-68.

PMID: 11735605 DOI: 10.2165/00003088-200140110-00004.


Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Talbot G, Cassileth P, Paradiso L, Bond L Antimicrob Agents Chemother. 1993; 37(3):474-82.

PMID: 8460916 PMC: 187695. DOI: 10.1128/AAC.37.3.474.


Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.

Waite N, Rybak M, Krakovsky D, Steinberg J, Warbasse L, Edwards D Antimicrob Agents Chemother. 1991; 35(1):130-4.

PMID: 2014968 PMC: 244953. DOI: 10.1128/AAC.35.1.130.


Pharmacokinetic interactions between theophylline and other medication (Part II).

Upton R Clin Pharmacokinet. 1991; 20(2):135-50.

PMID: 1709398 DOI: 10.2165/00003088-199120020-00005.


Drug interactions with quinolone antibacterials.

Brouwers J Drug Saf. 1992; 7(4):268-81.

PMID: 1524699 DOI: 10.2165/00002018-199207040-00003.

References
1.
Scott P, Tabachnik E, MacLeod S, Correia J, Newth C, Levison H . Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr. 1981; 99(3):476-9. DOI: 10.1016/s0022-3476(81)80354-x. View

2.
Wijnands W, Vree T, van Herwaarden C . The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986; 22(6):677-83. PMC: 1401213. DOI: 10.1111/j.1365-2125.1986.tb02957.x. View

3.
Rogge M, SOLOMON W, Sedman A, Welling P, Koup J, Wagner J . The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. Clin Pharmacol Ther. 1989; 46(4):420-8. DOI: 10.1038/clpt.1989.160. View

4.
Beckmann J, Elsasser W, Gundert-Remy U, Hertrampf R . Enoxacin--a potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol. 1987; 33(3):227-30. DOI: 10.1007/BF00637553. View

5.
Rogge M, SOLOMON W, Sedman A, Welling P, Toothaker R, Wagner J . The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther. 1988; 44(5):579-87. DOI: 10.1038/clpt.1988.197. View